Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2023-03-21 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure provides update on Karl Storz's commitment to maximize the commercial adoption of SaphiraT and decision to discontinue flexible BLC tower production in the U.S.
Regulatory Filings Classification · 100% confidence The document is a press release dated March 21, 2023, announcing a strategic update regarding the commercial adoption of the Saphira™ system and the discontinuation of flexible BLC tower production by Karl Storz. It details business decisions, product strategy, and market impact, which is characteristic of an Earnings Release (ER) or a general business update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification for a major business/operational announcement released via press release is Earnings Release (ER), as these often contain key operational highlights and management commentary, even if not strictly tied to quarterly results reporting dates. Given the content focuses on commercial strategy and partnership changes, ER is the best fit among the provided options for a significant, non-periodic business announcement.
2023-03-21 English
Photocure provides update on Karl Storz's commitment to maximize the commercial adoption of SaphiraT and decision to discontinue flexible BLC tower production in the U.S.
Regulatory Filings Classification · 100% confidence The document is a press release dated March 21, 2023, from Photocure ASA, announcing an update regarding its partnership with Karl Storz concerning the SaphiraT system and the discontinuation of flexible BLC tower production in the U.S. It contains operational updates, management commentary, and standard boilerplate information about the disease, the product, and the company. This format strongly suggests an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (like 10-K or IR) but rather an announcement of business developments and strategic decisions, it fits best as an Earnings Release (ER) if it accompanied quarterly results, or a Regulatory Filing (RNS) if it's a general, non-financial-specific announcement. Given the context of providing updates on commercial strategy and product lines, it functions as a key corporate announcement. However, it is not explicitly labeled as an 'Earnings Release' but rather an 'update'. Since it is a detailed announcement of business events and strategic changes, and not a short notice about a report being published (RPA), the most appropriate classification among the specific options is ER, as these types of operational updates often accompany earnings periods, or RNS as a general regulatory disclosure. Given the content focuses heavily on commercial strategy and partnership changes, and it is a formal press release, RNS is the safest general classification if ER is not confirmed to be tied to a specific earnings period announcement, but ER is often used for significant operational updates. Since it is a detailed press release announcing significant business developments, I will classify it as an Earnings Release (ER) as these often contain operational color, or RNS. Given the lack of explicit financial tables or summary figures typical of a pure ER, RNS (Regulatory Filings) is the most accurate fallback for a significant, non-standard filing.
2023-03-21 English
Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure ASA dated March 14, 2023, announcing their participation and abstract presentations at the European Association of Urology (EAU) congress. It details new data regarding their Blue Light Cystoscopy (BLC) technology for bladder cancer management. This type of announcement, which disseminates recent scientific or operational news via a formal press release, typically falls under general Investor Relations or Regulatory Filings. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), and it is an announcement of company activity/data rather than a formal regulatory filing like a DVA or DIRS, the most appropriate classification is a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the slides themselves. Given the format is a news release detailing scientific updates and participation in an event, RNS (Regulatory Filings - general regulatory announcements and fallback) is the best fit, as it is an official communication to the market about company-related developments.
2023-03-14 English
Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer
Earnings Release Classification · 93% confidence The document is a press release dated March 14, 2023, from Photocure ASA announcing its participation in the European Association of Urology (EAU) congress and highlighting two abstract presentations related to Blue Light Cystoscopy (BLC) for bladder cancer management. This type of announcement, detailing company activities, scientific presentations, and key findings outside of mandated periodic financial reports (like 10-K or IR), is characteristic of an Earnings Release (ER) or a general corporate/investor update. Since it focuses on recent scientific/conference activity rather than specific quarterly financial figures (which would suggest ER or IR), and it is a formal announcement distributed to the public/investors, it fits best under the 'Earnings Release' category as a general corporate update/news release, or potentially 'Regulatory Filings' (RNS) if it were less specific. Given the context of sharing news about scientific data presentation, 'ER' is often used for such press releases announcing corporate milestones or key developments, even if not strictly quarterly earnings. However, since it is a general corporate announcement about participation in a conference and presentation of data, and not a formal financial report or a specific regulatory filing like a director's dealing or capital change, the most appropriate general category for a press release announcing corporate news is often 'ER' (Earnings Release, used broadly for results/updates) or 'RNS' (Regulatory Filings/General Announcement). Given the content is a news announcement about scientific data, it is most closely aligned with the type of communication often released alongside or instead of a formal earnings report to update the market on key business developments. I will classify it as an Earnings Release (ER) as it serves as a primary update to the market, though RNS is a close secondary option. Q1 2023
2023-03-14 English
NOTIFICATION OF MAJOR HOLDINGS
Major Shareholding Notification Classification · 99% confidence The document is titled "Standard form for notification of major holdings" and explicitly details an acquisition/disposal of voting rights by 'Lannebo Fonder AB' in 'Photocure ASA' on 2023-02-24, crossing a threshold resulting in a 5.94% holding. This structure and content align perfectly with regulatory filings concerning changes in significant share ownership, which corresponds to the Major Shareholding Notification category.
2023-02-24 English
NOTIFICATION OF MAJOR HOLDINGS
Major Shareholding Notification Classification · 99% confidence The document text explicitly states "NOTIFICATION OF MAJOR HOLDINGS" and directs the user to an attachment on 'www.newsweb.no'. This strongly indicates a notification regarding significant share ownership changes. Based on the definitions, the code 'MRQ' (Major Shareholding Notification) is the most appropriate classification. Given the extremely short length (107 characters) and the instruction to 'Please see attachment', it could potentially be an RPA, but the content is a direct notification type, making MRQ more specific and accurate for the subject matter.
2023-02-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.